Covid19 Clinical Trial
Official title:
Observational Study of Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure
NCT number | NCT04641182 |
Other study ID # | 0001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 6, 2020 |
Est. completion date | September 16, 2020 |
Verified date | November 2020 |
Source | Pontificia Universidad Catolica de Chile |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The aim of this observational study is to evaluate the physiological and clinical effects of prone position in awake patients with respiratory failure due to COVID-19.
Status | Completed |
Enrollment | 66 |
Est. completion date | September 16, 2020 |
Est. primary completion date | August 16, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Hospitalized patients with confirmed or suspected COVID-19 pneumonia requiring more than 3 liters per minute of supplemental oxygen or a Fraction of Inspired Oxygen (FIO2) over 35% to keep Pulse Oximetry Saturation (SpO2) over 90% - Treating physician indicated prone position as instructed by the institutional protocol - Patient capable of changing position with minimal help from the personnel Exclusion Criteria: - Patient requiring immediate intubation - Patient requiring non-invasive mechanical ventilation - Respiratory Rate > 40, signs of respiratory fatigue or unconsciousness with inability to protect the airway - PaCO2 > 50mmHg - Hemodynamic instability (defined by Heart Rate > 120, Systolic Pressure < 90mmHg, Mean Arterial Pressure < 60mmHg or requiring vasopressor support) - Obesity with BMI > 40 (Body Mass Index: weight in kilograms and height in meters will be combined to attain BMI in kg/m2) - Persistent vomiting - Facial or thoracic trauma or recent surgery contraindicating the prone position - Pregnancy > 20 weeks |
Country | Name | City | State |
---|---|---|---|
Chile | Hospital Clinico Red de Salud UC - Christus | Santiago | Region Metropolitana |
Lead Sponsor | Collaborator |
---|---|
Pontificia Universidad Catolica de Chile |
Chile,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Dyspnea | Using a scale from 1 to 10 (from 1 no dyspnea to 10 maximum dyspnea) | At 28 days | |
Other | Comfort with the position | Using a scale from 1 to 4 (1 is very comfortable and 4 is very uncomfortable) | At 28 days | |
Other | Oxygen saturation | Using PAFI (PAFI: Index calculated by Pressure of Arterial Oxygen / Inspired Fraction of Oxygen) | At 28 days | |
Other | Oxygen saturation | Using SAFI (SAFI: Index calculated by Oxygen Saturation by Pulse Oximetry / Inspired Fraction of Oxygen) | At 28 days | |
Primary | Therapeutic failure | Defined by death or intubation or use of non-invasive ventilation | At 14 days | |
Primary | Mortality | Number of patients that die | At day 28 | |
Primary | Length of hospital stay | Number of days spent by the patients at the hospital | At 28 days | |
Primary | Days requiring high flow nasal oxygen | Number of days the patients require high flow nasal oxygen therapy | At 28 days | |
Primary | Days requiring supplemental oxygen | Number of days the patients require supplementary oxygen | At 28 days | |
Primary | Displacement of invasive devices during position changes | Unintentional displacement or removal of Invasive devices including : central and peripheric vascular catheters, urinary catheter and chest tubes | At 28 days | |
Primary | Occurrence of pressure ulcers on the anterior surface of the body | Number of patients that develope pressure ulcers on the anterior surface of the body | At 28 days | |
Secondary | Respiratory superinfection | Certified by a respiratory tract sample and culture | At 28 days | |
Secondary | Delirium | Defined by the Confusion Assessment Method (CAM) | At 28 days | |
Secondary | Caloric intake | Daily number of ingested calories (in kilocalories) by the patients is recorded | At 28 days | |
Secondary | Proteic intake | Daily number of ingested proteins (in grams) by the patients is recorded | At 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |